Murrayazolinine

Murrayazolinine is a pyranocarbazole alkaloid that induces apoptosis in cancer cells by downregulating the Akt/mTOR survival signaling pathway, triggering G2/M cell cycle arrest, ROS elevation, mitochondrial membrane depolarization, and caspase-3 activation. In preclinical in vitro assays against DLD-1 human colon cancer cells, it demonstrated potent cytotoxicity with an IC50 of 5.7 μM while exhibiting no cytotoxicity in non-cancerous HEK-293 and HaCaT cell lines at equivalent concentrations.

Origin & History

Murrayazolinine is a pyranocarbazole alkaloid isolated from the leaves of Murraya koenigii (curry leaf tree), a tropical and subtropical tree native to the Indian subcontinent, Sri Lanka, and Southeast Asia. The tree thrives in well-drained, fertile soils at low to mid elevations and is widely cultivated across South and Southeast Asia as a culinary and medicinal plant. The alkaloid itself is not commercially cultivated or harvested in isolation but is extracted from plant leaf material for research purposes using organic solvent extraction techniques.

Historical & Cultural Context

Murraya koenigii leaves have been used in Indian Ayurvedic medicine for centuries, with documented applications in the management of hyperglycemia, inflammatory conditions, piles, leucoderma, blood disorders, and bronchial complaints. The tree holds cultural significance in Hindu religious rituals and is considered an auspicious plant in several South Asian traditions, often grown in domestic gardens for both culinary and spiritual purposes. Classical Ayurvedic texts reference the leaves as having tikta (bitter) and kashaya (astringent) rasas, properties associated with anti-inflammatory and detoxifying actions. The isolation and characterization of specific alkaloids such as murrayazolinine represents a modern phytochemical effort to identify the molecular basis of these traditional claims, though the compound itself was not known or named in historical herbal practice.

Health Benefits

- **Anticancer Activity (Colon Cancer)**: Murrayazolinine suppresses proliferation of DLD-1 colon cancer cells with an IC50 of 5.7 μM, selectively sparing non-cancer HEK-293 and HaCaT cells, suggesting a favorable therapeutic window in preclinical models.
- **Apoptosis Induction**: The compound activates the intrinsic apoptotic pathway by increasing the Bax/Bcl-2 ratio and activating caspase-3, leading to programmed cell death specifically in malignant cell populations.
- **Cell Cycle Arrest**: Murrayazolinine promotes G2/M phase arrest in cancer cells, halting cellular replication and preventing tumor cell division as demonstrated in DLD-1 cell line studies.
- **Oxidative Stress Modulation in Cancer Cells**: The compound elevates intracellular reactive oxygen species (ROS) in cancer cells, contributing to mitochondrial membrane depolarization and subsequent apoptotic signaling.
- **Akt/mTOR Pathway Inhibition**: By downregulating the Akt/mTOR signaling axis, murrayazolinine disrupts a key pro-survival and pro-proliferative pathway frequently hyperactivated in colorectal and other solid-tumor cancers.
- **Anti-inflammatory Potential (Source Plant)**: As part of the broader alkaloid profile of Murraya koenigii leaves, murrayazolinine contributes to the plant's reported anti-inflammatory bioactivity, though specific molecular targets for this compound in inflammation have not been individually characterized.
- **Neuroprotective Context (Related Alkaloids)**: Closely related Murraya carbazole alkaloids—murrayanol and mahanimbine—inhibit acetylcholinesterase (AChE) with IC50 values of approximately 0.2 μg/mL and reduce amyloid-beta (Aβ) fibrillization, suggesting that the broader carbazole class from this botanical source may support neurological health, though this has not been confirmed for murrayazolinine specifically.

How It Works

Murrayazolinine exerts its primary characterized activity through downregulation of the Akt/mTOR intracellular signaling pathway, a critical regulator of cell survival, growth, and proliferation that is frequently dysregulated in colorectal cancers. This pathway suppression leads to downstream consequences including G2/M cell cycle arrest, preventing cancer cells from completing mitosis. Concurrently, the compound elevates intracellular reactive oxygen species (ROS), induces mitochondrial membrane depolarization, and shifts the balance of apoptosis-regulatory proteins toward cell death by increasing the Bax/Bcl-2 ratio and activating executioner caspase-3. The compound's selectivity for cancer versus non-cancer cells—evidenced by absence of cytotoxicity in HEK-293 and HaCaT lines—implies a mechanistic dependence on the aberrant signaling environment characteristic of transformed cells, though the precise receptor or binding-site interactions governing this selectivity have not yet been fully elucidated.

Scientific Research

The entire evidence base for murrayazolinine consists of preclinical in vitro studies; no animal (in vivo) studies or human clinical trials have been published as of the available literature. The most robust data originate from cell-line experiments using DLD-1 human colon adenocarcinoma cells, where an IC50 of 5.7 μM was established alongside mechanistic assays confirming Akt/mTOR downregulation, caspase-3 activation, and ROS elevation. Comparative in vitro studies on structurally related Murraya koenigii carbazoles (murrayanol, mahanimbine, O-methylmurrayamine A) provide contextual mechanistic insight, including AChE inhibition and Aβ fibrillization data, but these findings cannot be directly attributed to murrayazolinine. Researchers in the field explicitly recommend controlled clinical trials to validate the anticancer and neuroprotective claims derived from these herbal alkaloids, underscoring the early-stage nature of the evidence.

Clinical Summary

No clinical trials investigating murrayazolinine as an isolated compound or as a standardized component of Murraya koenigii extract have been conducted or registered. All quantified efficacy data derive exclusively from in vitro cell-line experiments, providing no information on pharmacokinetics, effective human doses, tolerability, or comparative clinical outcomes. The IC50 of 5.7 μM in DLD-1 colon cancer cells represents a cellular potency metric only and cannot be extrapolated to human therapeutic doses without bioavailability, distribution, and safety data. Confidence in any clinical benefit is therefore very low, and murrayazolinine should be regarded strictly as a research-stage phytochemical compound with unproven clinical utility.

Nutritional Profile

Murrayazolinine as an isolated alkaloid compound does not possess a conventional nutritional profile (macronutrients, vitamins, minerals). As a pyranocarbazole alkaloid, it is a nitrogen-containing secondary metabolite with a molecular structure comprising a carbazole tricyclic aromatic core fused with a pyran ring system. Its concentration in Murraya koenigii leaf material has not been quantified in available published literature. Whole Murraya koenigii leaves, from which it derives, contain dietary fiber, essential oils (sabinene, β-gurjunene), carbazole alkaloids (mahanimbine, murrayanol, murrayafoline A), flavonoids, and minerals (iron, calcium), but these nutritional components are not attributed to murrayazolinine specifically. Bioavailability of the alkaloid from whole-leaf consumption is predicted to be limited based on in silico ADMET modeling of structurally related carbazole compounds showing poor solubility and absorption.

Preparation & Dosage

- **Research-Grade Isolated Compound**: Murrayazolinine is isolated from Murraya koenigii leaf material via organic solvent extraction (e.g., methanol or ethanol) followed by chromatographic purification; no commercial supplement form exists.
- **Traditional Leaf Consumption (Whole Plant)**: Fresh or dried curry leaves are consumed as a culinary spice in South and Southeast Asian cooking; typical culinary use involves 5–15 leaves per meal, but this is not a medicinal dose of isolated alkaloid.
- **Ayurvedic Decoction (Source Plant)**: Traditional Ayurvedic preparations use dried Murraya koenigii leaf powder (1–3 g) or decoctions (10–20 g dried leaf boiled in water), though alkaloid content in these preparations is unstandardized.
- **Standardized Supplement**: No commercially standardized extract specifying murrayazolinine content is available; no effective dose range from clinical trials can be cited.
- **Bioavailability Note**: In silico ADMET modeling of related Murraya carbazoles (e.g., murrayanol, mahanimbine) predicts poor aqueous solubility and limited oral absorption, suggesting that meaningful bioavailability of murrayazolinine from whole-leaf consumption may be low without formulation enhancement.

Synergy & Pairings

No empirically validated synergistic combinations for murrayazolinine have been studied. Within the Murraya koenigii alkaloid complex, murrayazolinine co-occurs with mahanimbine and murrayanol, which inhibit acetylcholinesterase and reduce amyloid-beta fibrillization, suggesting that whole-leaf or multi-alkaloid extracts may provide broader bioactivity than any single isolated compound—a theoretical synergy consistent with the entourage concept in phytochemistry. In preclinical oncology contexts, compounds targeting the Akt/mTOR pathway (as murrayazolinine does) have shown additive or synergistic effects when combined with PI3K inhibitors or conventional chemotherapeutics such as 5-fluorouracil, though no such combinations have been tested with murrayazolinine specifically.

Safety & Interactions

Murrayazolinine has demonstrated no cytotoxicity against non-cancerous human cell lines (HEK-293 embryonic kidney cells and HaCaT keratinocytes) at concentrations effective against DLD-1 colon cancer cells in vitro, suggesting a preliminary favorable selectivity index. However, no human safety data exist—including no clinical adverse effect profiles, maximum tolerated dose, organ toxicity data, or pharmacovigilance reports—as the compound has not been studied in humans or in animal models. Drug interaction potential is entirely unstudied; theoretical concerns exist for co-administration with mTOR inhibitors (e.g., everolimus, sirolimus), chemotherapeutic agents, or anticoagulants given the bioactive alkaloid nature of the compound, but no empirical interaction data are available. Murraya koenigii leaves as a whole food are generally regarded as safe in traditional culinary use; however, isolated or concentrated murrayazolinine cannot be assumed safe based on leaf safety alone, and use in pregnancy, lactation, or pediatric populations cannot be evaluated without human data.